Brain Glucose Metabolism Imaging: How FDG-PET Scans Map Neural Activity

Positron Emission Tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) is the premier technique for visualizing regional brain glucose metabolism, a proxy for synaptic activity.

Principle

  1. Tracer injection: 18F-FDG (glucose analog with radioactive fluorine-18) injected IV.
  2. Uptake: Glucose transporters (GLUT1/3) move FDG into neurons and glia proportional to metabolic demand.
  3. Trapping: Hexokinase phosphorylates FDG → FDG-6-phosphate, which cannot proceed in glycolysis nor exit cell (no phosphatase). Accumulates in active cells.
  4. Decay & detection: 18F decays (t½=110 min) emitting positrons → annihilation with electrons → paired 511 keV gamma photons detected by PET ring.
  5. Image reconstruction: Coincidence detection localizes emission → 3D metabolic map.

Clinical & Research Applications

  • Neurodegeneration: Alzheimer's (temporoparietal hypometabolism), frontotemporal dementia (frontal), Lewy body (occipital).
  • Epilepsy: Interictal hypometabolism localizes seizure focus for surgery.
  • Brain tumors: Grading (high-grade = hypermetabolic), recurrence vs. necrosis.
  • Psychiatry: Schizophrenia (hypofrontality), depression, OCD circuit mapping.
  • Cognitive neuroscience: Task-activated metabolism (though fMRI has better temporal resolution).

Procedure

  • Fasting 4–6 hr (normalizes blood glucose, reduces competition).
  • Quiet, dim room during uptake (30–60 min) to minimize sensory-driven metabolism.
  • Scan: 10–20 min. Radiation dose ~7 mSv (comparable to abdominal CT).

Limitations

  • Low spatial resolution (~4–6 mm) vs. MRI.
  • No direct neurotransmitter info (requires specific radioligands).
  • Cost, cyclotron access, radiation exposure.

FDG-PET remains indispensable for differential diagnosis of dementias, epilepsy surgery planning, and oncology.

Diabetes - Related Articles